Cognition Therapeutics, Inc.CGTXNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank64
3Y CAGR-52.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-52.8%/yr
Quarterly compound
Percentile
P64
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 4.21% |
| Q2 2025 | -16.46% |
| Q1 2025 | 16.35% |
| Q4 2024 | -16.35% |
| Q3 2024 | -0.97% |
| Q2 2024 | -11.17% |
| Q1 2024 | -2.73% |
| Q4 2023 | 16.68% |
| Q3 2023 | -7.35% |
| Q2 2023 | -6.29% |
| Q1 2023 | 23.88% |
| Q4 2022 | -34.36% |
| Q3 2022 | 39.87% |
| Q2 2022 | 7.60% |
| Q1 2022 | -53.57% |
| Q4 2021 | 302.78% |
| Q3 2021 | 42.02% |
| Q2 2021 | -5.46% |
| Q1 2021 | 38.42% |
| Q4 2020 | -21.56% |
| Q3 2020 | -10.00% |
| Q2 2020 | -18.34% |
| Q1 2020 | 0.00% |